Matinas BioPharma (NYSEAMERICAN:MTNB) Given Hold Rating at Maxim Group

Maxim Group reissued their hold rating on shares of Matinas BioPharma (NYSEAMERICAN:MTNB) in a report issued on Thursday, MarketBeat reports.

Matinas BioPharma Stock Performance

Shares of NYSEAMERICAN MTNB opened at $0.58 on Thursday. Matinas BioPharma has a 1 year low of $0.54 and a 1 year high of $21.50. The stock has a market cap of $2.92 million, a P/E ratio of -0.11 and a beta of 1.73.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02).

Institutional Investors Weigh In On Matinas BioPharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. Alliance Wealth Management Group bought a new stake in Matinas BioPharma in the second quarter worth $299,000. Towercrest Capital Management bought a new position in Matinas BioPharma in the 2nd quarter worth about $299,000. Finally, Highbridge Capital Management LLC purchased a new stake in Matinas BioPharma during the 2nd quarter valued at about $1,685,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.